F10 and neoplasm: Our finding is entirely consistent with results from preclinical studies, which demonstrated that specifically FXa DOACs augment anti-tumor immunity by promoting an accumulation of CTL and DC in the TME, while preventing the recruitment of regulatory T cells (Treg) and macrophage polarization towards an immunosuppressive phenotype [12].